atezolizumab
roche
['dante', 'atezo']
dante ph2 trial:
periop flot +/- atezo in gea: 8.5% msi; 50% pd-l1+, 23% pd-l1 cps 5 downsizing (pt0, 23% vs 15%; pn0, 68% vs 54%) post-op compl. in 43% promising activity (matterhorn ongoing) should we consider trials with all chemo pre-op? #asco22
Brazilian Medical Oncologist, Advanced Fellow at GI Medical Oncology Service - MSKCC #gicancers